Skip to main content
TipRanks
Go Ultimate75% OFF

FluoGuide A/S (FLUO) AI Stock Analysis

1 Followers
SE:FLUO

FluoGuide A/S

(Nasdaq OMX AB:FLUO)

Select Model
Rating:40Underperform
Price Target:SEK 27.00â–¼(-14.56% Downside)
Action:downgraded
Date:08/27/26

FluoGuide scores near the low end of the range, driven primarily by weak financials: essentially zero revenue, a widening 46.2 million net loss, and 44.3 million of annual cash burn against only 30.7 million of remaining equity. Leverage rose from near zero to roughly 0.9 times equity in a single year, adding refinancing and dilution risk to an already tight runway. Technicals reinforce the caution, with the price below all major moving averages and negative MACD momentum. Valuation provides no cushion — earnings are negative and no dividend is paid. The investment case rests entirely on clinical pipeline progress and the ability to raise capital, not on current financial performance.

Positive Factors
Proprietary fluorescence imaging platformThe proprietary fluorescence-guided surgery platform targets a clear clinical need: improving tumor visualization while sparing healthy structures. If development and approvals succeed, this focused technology could support product sales, licensing, or partnerships across oncology surgery markets.
Negative Factors
Minimal and declining revenueThe very small and declining revenue base shows that FluoGuide has not yet established meaningful commercial scale. With revenue far below the cost base, the company remains highly dependent on successful development, regulatory progress, and eventual commercialization.

FluoGuide A/S (FLUO) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:FLUO-17.28%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 459.42M
Dividend Yield
―
Average Volume (3M)
5,056
Price to Earnings (P/E)
-7.1
Beta (1Y)
0.11
Revenue Growth
―
EPS Growth
-23.57%
Country
Sweden
Employees
7
Sector
General
Sector Strength
55
Industry
Biotechnology

FluoGuide A/S Business Overview & Revenue Model

Company Description

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade g...

How the Company Makes Money

FluoGuide’s business model is centered on developing proprietary fluorescence imaging agents and monetizing them through (1) future commercial sales (if/when regulatory approvals are obtained) and/or (2) partnering and licensing transactions with lar...

FluoGuide A/S Financial Statement Overview

Summary

All three financial verticals score poorly. Revenue has effectively vanished (just 54 thousand in the TTM period), while the net loss widened to 46.2 million and operating loss to 48.5 million. Cash burn is the sharpest concern: free cash flow of -44.3 million has worsened for three straight years and now exceeds the entire 30.7 million equity base. The balance sheet is the relative bright spot but is deteriorating — equity fell from 54.6 million to 30.7 million and debt jumped from near zero to 27.6 million, lifting debt-to-equity to roughly 0.90. The company is fully dependent on external funding, with likely dilution or refinancing within about a year. Spending is directed at pipeline development rather than covering commercial shortfalls, and capital expenditure is negligible, which provides modest offset.

Income Statement

9Very Negative

Balance Sheet

33Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue54.00K0385.00K423.00K6.51M9.61M
Gross Profit-416.92K-571.17K385.00K423.00K6.51M9.61M
EBITDA-48.08M-40.42M-32.58M-43.66M-32.21M-28.65M
Net Income-46.24M-40.39M-28.96M-38.38M-27.34M-23.77M
Balance Sheet
Total Assets65.25M88.34M28.38M29.61M35.62M53.31M
Cash, Cash Equivalents and Short-Term Investments49.92M78.84M18.61M21.67M26.01M46.76M
Total Debt27.56M28.30M624.00K10.83M205.00K57.00K
Total Liabilities34.51M33.78M5.31M16.89M3.65M14.61M
Stockholders Equity30.74M54.56M23.07M12.72M31.97M38.70M
Cash Flow
Free Cash Flow-44.28M-37.83M-30.00M-31.81M-37.71M-15.06M
Operating Cash Flow-43.80M-37.83M-29.15M-31.81M-37.65M-15.06M
Investing Cash Flow-30.37M-30.61M-987.00K-37.00K-117.00K0
Financing Cash Flow74.76M99.33M27.08M27.50M17.02M51.18M

FluoGuide A/S Technical Analysis

Technical Analysis SentimentNegative
Last Price31.60

Price Trends

50DMA32.03Negative
100DMA32.94Negative
200DMA36.18Negative

Market Momentum

MACD-0.84Positive
RSI36.13Neutral
STOCH23.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 31.60 is above the 20-day moving average (MA) of 30.14, below the 50-day MA of 32.03, and below the 200-day MA of 36.18, indicating a bearish trend. The MACD of -0.84 indicates Positive momentum. The RSI at 36.13 is Neutral, neither overbought nor oversold. The STOCH value of 23.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.

FluoGuide A/S Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:FLUO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:FLUISE:FLUI65NeutralSEK 32.83M6.3734.47%―630.57%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:BINVSE:BINV49NeutralSEK 172.08M-0.35-128.54%―-83.67%-50.29%
SE:ONCOSE:ONCO44NeutralSEK 747.11M-2.67――65.37%43.28%
SE:SPAGOSE:SPAGO42NeutralSEK 35.13M-1.05-87.37%―-97.52%31.31%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 86.35M-1.21-75.51%―56.06%63.95%
SE:FLUOSE:FLUO40UnderperformSEK 516.64M-7.06―――-23.57%

* General Sector Average

Performance Comparison

0%100%200%300%SE:FLUOSE:BINVSE:ONCOSE:BIOVIC.BSE:SPAGOSE:FLUIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:FLUO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:FLUOFluoGuide A/S31.60-8.10-20.40%
SE:BINVBioInvent International AB2.62-28.28-91.54%
SE:ONCOOncopeptides AB1.68-3.29-66.19%
SE:BIOVIC.BBiovica International AB Class B0.30-0.23-43.82%
SE:SPAGOSpago Nanomedical AB0.04-0.06-59.00%
SE:FLUIFluicell AB23.0011.4098.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026